HAEMONETICS CORP — Director's Dealing 2011

May 18, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2011-05-16

Reporting Person: Gordon Mikael (President, Haemonetics Europe)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-05-16	Common Stock	S	100.0	$67.28	Disposed	5901.0	Direct
2011-05-16	Common Stock	S	357.0	$67.27	Disposed	5544.0	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$52.94	2016-10-27	Common Stock (19587.0)	19587.0	Direct
Non-Qualified Stock Option (right to buy)	$54.55	2015-10-22	Common Stock (15247.0)	15247.0	Direct
Non-Qualified Stock Option (right to buy)	$54.99	2017-10-27	Common Stock (18940.0)	18940.0	Direct
Non-Qualified Stock Option (right to buy)	$55.14	2015-01-22	Common Stock (18980.0)	18980.0	Direct

Footnotes

F1: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.